112 related articles for article (PubMed ID: 6448687)
1. Initial clinical study with N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with advanced cancer.
Hart RD; Ohnuma T; Holland JF
Cancer Treat Rep; 1980; 64(4-5):617-24. PubMed ID: 6448687
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of N-(Phosphonacetyl)-L-aspartic acid (PALA).
Ervin TJ; Blum RH; Meshad MW; Kufe DW; Johnson RK; Canellos GP
Cancer Treat Rep; 1980; 64(10-11):1067-71. PubMed ID: 7459892
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of N-(phosphonacetyl)-L-aspartic acid (PALA).
Kovach JS; Schutt AJ; Moertel CG; O'Connell MJ
Cancer Treat Rep; 1979; 63(11-12):1909-12. PubMed ID: 526923
[TBL] [Abstract][Full Text] [Related]
4. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in metastatic adenocarcinoma of the colon or rectum.
Van Echo DA; Diggs CH; Scoltock M; Wiernik PH
Cancer Treat Rep; 1980; 64(2-3):339-42. PubMed ID: 7407767
[TBL] [Abstract][Full Text] [Related]
5. N-(phosphonacetyl)-L-aspartate (PALA) in advanced malignant melanoma: a phase II trial of the EORTC Malignant Melanoma Cooperative Group.
Kleeberg UR; Mulder JH; Rümke P; Thomas D; Rozencweig M
Eur J Cancer Clin Oncol; 1982 Aug; 18(8):723-6. PubMed ID: 6217975
[TBL] [Abstract][Full Text] [Related]
6. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with non-small cell carcinoma of the lung.
Casper ES; Gralla RJ; Kelsen DP; Houghton A; Golbey RB; Young CW
Cancer Treat Rep; 1980; 64(4-5):705-7. PubMed ID: 6448688
[No Abstract] [Full Text] [Related]
7. Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
Erlichman C; Donehower RC; Speyer JL; Klecker R; Chabner BA
J Natl Cancer Inst; 1982 Feb; 68(2):227-31. PubMed ID: 6950156
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
Grem JL; McAtee N; Steinberg SM; Hamilton JM; Murphy RF; Drake J; Chisena T; Balis F; Cysyk R; Arbuck SG
Cancer Res; 1993 Oct; 53(20):4828-36. PubMed ID: 8402669
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.
Ardalan B; Singh G; Silberman H
J Clin Oncol; 1988 Jun; 6(6):1053-8. PubMed ID: 3373260
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial of combination therapy with continuous-infusion PALA and continuous-infusion 5-FU.
Weiss GR; Ervin TJ; Meshad MW; Schade D; Branfman AR; Bruni RJ; Chadwick M; Kufe DW
Cancer Chemother Pharmacol; 1982; 8(3):301-4. PubMed ID: 7127661
[TBL] [Abstract][Full Text] [Related]
11. Phase II evaluation of N-(phosphonacetyl-L-aspartic acid (PALA) in patients with advanced colorectal carcinoma.
Carroll DS; Gralla RJ; Kemeny NE
Cancer Treat Rep; 1980; 64(2-3):349-51. PubMed ID: 7407769
[No Abstract] [Full Text] [Related]
12. Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study.
Chiuten DF; Miller A; Valdivieso M; Loo TL; Bedikian A; Bodey GP; Benvenuto JA; Freireich EJ
Am J Clin Oncol; 1985 Aug; 8(4):332-5. PubMed ID: 4083263
[TBL] [Abstract][Full Text] [Related]
13. N-(phosphonacetyl)-L-aspartate (PALA) in advanced breast cancer: a phase II trial of the EORTC breast cancer cooperative group.
Paridaens R; Mouridsen HT; Palshof T; Cocconi G; Van Oosterom A; Rotmensz N; Sylvester R; Heuson JC; Rozencweig M
Eur J Cancer Clin Oncol; 1982 Jan; 18(1):67-70. PubMed ID: 6211361
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of N-(phosphonacetyl)-L-aspartate.
Erlichman C; Strong JM; Wiernik PH; McAvoy LM; Cohen MH; Levine AS; Hubbard SM; Chabner BA
Cancer Res; 1979 Oct; 39(10):3992-5. PubMed ID: 157801
[TBL] [Abstract][Full Text] [Related]
15. PALA (NSC-224131) in advanced carcinoma of the cervix. A phase II study of the Gynecologic Oncology Group.
Muss HB; Bundy B; DiSaia PJ; Stehman FB; Beecham J
Am J Clin Oncol; 1984 Dec; 7(6):741-4. PubMed ID: 6528869
[TBL] [Abstract][Full Text] [Related]
16. N-(phosphonacetyl)-L-aspartate (PALA) in advanced soft tissue sarcoma: a phase II trial of the EORTC soft tissue sarcoma group.
Bramwell V; Van Oosterom A; Mouridsen HT; Cheix F; Somers R; Thomas D; Rozencweig M
Eur J Cancer Clin Oncol; 1982 Jan; 18(1):81-4. PubMed ID: 6211362
[TBL] [Abstract][Full Text] [Related]
17. Treatment of psoriasis with N-phosphonacetyl-L-aspartate.
Doyle JA; Perry HO; Rubin J; Moertel CG
J Am Acad Dermatol; 1984 Jan; 10(1):21-4. PubMed ID: 6229552
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of continuous-infusion PALA and 5-FU.
Ardalan B; Jamin D; Jayaram HN; Presant CA
Cancer Treat Rep; 1984 Mar; 68(3):531-4. PubMed ID: 6231102
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of PALA in lymphoma: an Eastern Cooperative Oncology Group study.
Muggia FM; Tsiatis AA; O'Connell MJ; Glick JH; Opfell RW; Coren A
Cancer Treat Rep; 1984 Mar; 68(3):551-3. PubMed ID: 6231103
[TBL] [Abstract][Full Text] [Related]
20. A comparative study of PALA, PALA plus 5-FU, and 5-FU in advanced breast cancer.
Mann GB; Hortobagyi GN; Buzdar AU; Yap HY; Valdivieso M
Cancer; 1985 Sep; 56(6):1320-4. PubMed ID: 4027872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
